Todd Applebaum

Despite the current regulatory uncertainty, pharmaceutical companies should move forward with planning for serialization and pedigree.

Companies need to avoid operating in a manner that is inconsistent with the priorities established in the strategic sourcing decision.

The supply chain can be used as a tool for managing not only product supply risks, but overall business risks as well.

Many CMO relationships are established while a product is early in clinical or preclinical development.